Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
February 26, 2021
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Ursula, and I'll be the conference operator for today's session. I'd like to welcome all of you to Cronos Group's 2020 Fourth Quarter and Full Year Earnings Conference Call. This call is being recorded today. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, please go ahead.
Shayne Laidlaw
executiveThanks, Ursula, and thanks to everyone for being with us today as we go over Cronos Group's financial and business results for the fourth quarter and the full year of 2020. With me today are Kurt Schmidt, our President and CEO; Jerry Barbato, our CFO; Mike Gorenstein, our Executive Chairman; and Xiuming Shum, our EVP of Legal and Regulatory Affairs. This morning Cronos Group put out a news release announcing its financial results, and those are filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before handing the call to Kurt, I want to remind everyone that what we discuss on this conference call will include forward-looking statements. Those statements rest on assumptions that carry risks and uncertainties, and actual results could therefore differ materially from what the forward-looking statements project, including because of the factors set out in the cautionary statement and the risk factors contained in the Company's earnings release and regulatory filings, among them the company's most recent annual report on Form 10-K filed today, and any forward-looking statements made on this call are qualified in their entirety by those documents. Also, on this call we may discuss certain financial measures that are not recognized under the U.S.
Shayne Laidlaw
executiveThe SEC refers to figures outside Generally Accepted Accounting Principles as non-GAAP measures. In our view, these non-GAAP measures help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You can find reconciliations of these non-GAAP measures to the nearest reported GAAP measures in our earnings press release furnished to the SEC, which is posted in the press room section of our website, thecronosgroup.com. Measures of this kind might not be comparable to those other issuers use. I'd also like to mention that we are holding today's call from our separate remote locations. Because of that, brief delays, cross talk, or minor technical issues could occur during this call. We thank you ahead of time for your patience and understanding. We will now deliver prepared remarks, and after that we'll move to a question-and-answer session. With that, I'll hand things over to Cronos Group's President and CEO, Kurt Schmidt.
Kurt Schmidt
executiveThank you, Shayne. Now that we're moving into 2021 and looking back at 2020, what the Cronos team managed to get done — particularly in such a complicated operating environment — was truly impressive. I'm very eager to see what we'll be able to achieve in 2021 and beyond. I want to pause here to acknowledge and express my gratitude to our team around the world for pushing through the difficulties the world encountered in 2020 and keeps encountering in 2021. I'll kick off this morning's call by looking back at a handful of 2020 highlights and talking about our plan to succeed in 2021. Over the six months since I came to Cronos, I've concentrated on helping speed up growth and preparing our future strategy. Together with Mike, our dedicated team, and the leadership group, we've zeroed in on the areas we want to prioritize as an organization. During 2021, we intend to center on four key pillars in order to generate business results and growth throughout the organization. Pillar one is making sure we keep building a winning team. My plan is to back our employees by cultivating a collaborative, performance-driven culture that aims to win. We recognize that this fast-growing industry calls for skilled and thoughtful employees, and I intend to keep nurturing a winning, collaborative spirit so our teams can execute as we expand in current markets and into new ones, support our brands, and carry on our R&D efforts in 2021.
Kurt Schmidt
executiveThe second pillar involves a sharp emphasis on creating disruptive tech and innovation, something that has consistently been a central strategic priority for Cronos. We remain convinced that putting money into innovation and breakthrough research will unlock cannabis's potential and give us a competitive edge over the long term. The third pillar, which I discussed during our last call, is about establishing excellent cannabis brands in the market at my core, and during 2021, we intend to keep innovating with our brands, aiming to satisfy consumer needs and go beyond their expectations. I take immense pride in the way we're growing our brands throughout our markets. Our attention will be on strong marketing approaches and fresh retail partnerships so we can reach additional consumers in 2021. The fourth pillar is about reinforcing our capacity to compete, and the first three pillars provide the foundation for this. Our efforts will center on creating competitive advantage via R&D strengths, globally positioned infrastructure, and participation in the legislative process within the markets that are important to us. That covers honing our strategic emphasis across Canada, Israel and the U.S. so that we keep generating long-term value and get the company ready for fresh opportunities whenever they emerge in 2021 and afterward.
Kurt Schmidt
executiveIt’s been a busy year. Still, we’re eager to keep executing our strategy and create long-term value for shareholders. 2021 is also looking like a significant period for U.S. cannabis legislation. I’d like to offer a few thoughts about legalization efforts and about how Cronos is participating to make sure we have a seat at the table. Legalization in various forms keeps spreading across the U.S., and the vast majority of Americans now reside in states where cannabis has been legalized in some form—medical, adult use, or both. Since many Americans voiced support for cannabis legalization in some form during this past election, momentum keeps building at both the state and federal level. We believe cannabis should be legal at the federal level, and that a comprehensive and reasonable federal regulatory framework should be put in place for the industry. In our view, the framework should establish product and safety standards for the industry and address critical societal considerations such as youth access prevention and social justice issues. As part of our focus and our participation in these efforts, it was announced a few weeks ago that Cronos is joining industry colleagues as a founding member of the U.S.
Kurt Schmidt
executiveTurning to the Cannabis Council, or USCC. Bringing together prominent cannabis and social justice groups from across North America, the USCC is set to become the leading trade association in the U.S. for cannabis thought leadership, innovation, and social responsibility. We're eager to work alongside our industry peers to push cannabis legalization forward in the U.S. As we've mentioned before, Mike Gorenstein's focus as Executive Chairman is on reviewing many opportunities and figuring out the optimal way for us to take part. He's put together an internal team to examine the various market opportunities and the different strategies we might use to enter. We're confident that with our balance sheet, our existing CBD infrastructure, and our strategic investor, we'll be a best-in-class cannabis company in the U.S. Jerry will cover the fourth quarter results, but I wanted to take a moment to highlight the annual performance. In fiscal year 2020, on a consolidated basis, revenue rose 97% year-over-year to $46.7 million, with strong performance across all regions. Our Rest of World segment posted net revenue of $37.2 million in fiscal year 2020, an 83% increase year-over-year. And finally, the United States segment, in its first full year of operations under the Cronos umbrella, reported net revenue of $9.5 million in fiscal year 2020.
Kurt Schmidt
executiveFollowing a so-so third quarter, the U.S. team returned with real strength in the fourth quarter and got the job done. That said, our U.S. CBD business is still steering through choppy waters — retail closures and other effects of the COVID-19 pandemic are behind that — yet we have faith that the team will keep running successfully within this climate. One essential driver of results for our U.S. CBD business was the successful launch of Happy Dance, our new skincare and personal care brands, done in partnership with Kristen Bell. Today we announced an exciting expansion for Happy Dance by landing its first major U.S. retailers, ULTA Beauty — the brand's first brick and mortar retail rollout. Happy Dance offers an easy-to-use line of cleaning and cruelty-free hemp derived CBD bath and body products. The full collection is expected to launch in the coming weeks on ulta.com, and shortly after that in store at over 550 ULTA locations across the U.S. We're incredibly excited to be partnering with ULTA and look forward to bringing the brand to a broader audience through ULTA's retail network. Broadening our distribution capabilities is an important next step in the evolution of this brand, which will be followed by additional product launches to stand variety for our consumers.
Kurt Schmidt
executiveDuring Q4, Lord Jones — the U.S. CBD brand we've positioned in prestige — introduced a new CBD lip balm made with a whole plant formula, and consumers have responded well to it. By adding entry level items to the Lord Jones lineup, we make the brand easier to access and encourage more people to try it. Lord Jones' Acid Mentle Repair Cream picked up the prestigious Refinery29 Beauty award during Q4 2020. The self-care and beauty category gives people a break from everyday stress, and we feel lucky that we can keep delivering high-quality products to U.S. consumers throughout this period. We intend to keep growing our innovative product portfolio in 2021. In Canada, we're continuing to widen our distribution throughout the retail landscape. We let consumer insights guide our decisions, while drawing on our strong R&D and innovation teams to launch products that consumers actually want. Our innovation funnel is off to the top, yet it's our consumer insights that let us concentrate on what consumers want today, while also watching for what they might want down the road. On that note, as those parts of the industry have expanded and consumer adoption rises, we're eager to pursue these further opportunities with innovative products in 2021.
Kurt Schmidt
executiveThe Spinach brand is still delivering strong results. Also, during the quarter just ended, Time Magazine named Spinach's Dancehall strain the Best Hybrid Dry Flower of The Year. We value this recognition particularly because bud tenders throughout our Canadian retail network put our name forward. While COVID-19 restricts our capacity for in-person engagement, retail marketing opportunities will be a key focus area for adult use brands, and we look forward to connecting with more consumers in retail spaces during 2021, since our marketing strategies are expected to concentrate heavily on this channel. Turning to the Israeli medical market, we are pleased to watch it keep growing, with approximately 80,000 medical patients now in the country. During Q4, Cronos Israel started selling Peace Naturals branded oil, in addition to the flower products launched earlier, to medical patients. Thanks to these successful launches, Cronos Israel has been able to rapidly establish its distribution network and build brand awareness via an expanding network of pharmacies. In February 2021, Cronos Israel entered into a distribution agreement with Super-Pharm, the biggest pharmacy chain in Israel, which operates more than 250 branches there. As our share grows, the pie itself is getting bigger too, with a rising number of pharmacies in Israel seeking to carry medical cannabis products, which creates a significant growth opportunity for the industry.
Kurt Schmidt
executiveThe Piece Natural brand has already earned recognition from the Israeli Marketing Association for its successful launch marketing strategy in 2020, which generated exposure for the Peace Natural brand among patients and also set the brand apart by showcasing its high quality relative to competitors. It's really gratifying to witness the sales volume and the resonance we're seeing with patients in this region. A key element of our R&D and innovation efforts remains the biosynthesis work we do at Cronos Fermentation in Winnipeg, together with Ginkgo Bioworks. After the successful fermentation of CBG and our Winnipeg R&D labs at research scale in the second quarter of 2020, the team has kept optimizing for scale and downstream processing and getting ready for commercialization. Cronos is putting priority on rare cannabinoids like CBG — though common ones such as THC and CBD too — and on plants to sequence commercial production, with product launches to follow based on this approach. Canada is a vital platform for us to develop innovative products so they're ready for other markets, including the U.S. and Israel, as regulations permit. We're eager to leverage our R&D, innovation and consumer insights to drive creation of differentiated products through consumer learnings as part of the commercialization plan.
Kurt Schmidt
executiveWhen it comes to innovation, we think that delivering rare cannabinoids at a meaningful scale could lift and set apart the consumer experience. We're eager to take the insights we have now and to build new ones over time around how consumers accept these innovative products. In short, during this past quarter, the sum of the hard work our teams have devoted over the past year is positive. Looking ahead to 2021, I'm extremely excited about the teams supporting our brands, and about all the R&D, innovation and exciting plans we have in store. With that, I'll hand the call over to our CFO, Jerry Barbato. Jerry?
Jerry Barbato
executiveThanks, Kurt, and good morning to everyone. Before we get into our financial performance, let me briefly address a change in the metrics we report. Rather than reporting operating income results at the segment level, we are moving to reporting adjusted EBITDA at the segment level. In our view, this gives a more representative picture of our business, and it assists management's review of performance and capital allocation. We also hope it further assists the investment community in evaluating how our business is performing. We review these results on an adjusted basis, which excludes certain non-cash items that may be highly variable, unusual or infrequent, in order to store underlying business trends and results. For more details on how we calculate adjusted EBITDA, please see our earnings press release, which is available on our website thecronosgroup.com on the Investors page. Turning to our financial results, the company reported consolidated net revenue of $17 million in the fourth quarter of 2020, a 133% increase from the prior year period. Revenue growth year-over-year was primarily driven by growth in the adult use Canadian cannabis market, sales in the Israeli medical market and growth in our U.S. hemp derived CBD business, partially offset by non-recurring wholesale revenue in the Canadian market in the fourth quarter of 2019 and strategic price reductions on various adult use cannabis products in Canada in the fourth quarter of 2020.
Jerry Barbato
executiveFor the fourth quarter of 2020, our consolidated gross loss came in at $14.9 million, which is a $5.2 million reduction in losses compared with the fourth quarter of 2019. The year-over-year improvement was mainly the result of lower inventory write-downs as well as a bigger gross profit contribution out of the U.S. segment. That was partly offset by higher cost of sales, driven largely by third-party purchase flower and by a decline in wholesale sales within the Canadian market. Pricing pressures in the marketplace could lead us to record additional inventory write-downs going forward. Adjusted EBITDA loss for the fourth quarter of 2020 totaled $53.1 million, which represents a $1.5 million increase in losses versus the fourth quarter of 2019. That year-over-year increase in losses was primarily attributable to higher general and administrative expenses along with greater R&D spending. Now moving to our reporting segments. Within the Rest of World segment, net revenue for the fourth quarter of 2020 was $13.5 million, up 193% from the prior year period. The year-over-year revenue growth was mainly fueled by continued expansion of the adult use Canadian cannabis market and by growth in the Israeli medical cannabis market, partially offset by non-recurring wholesale revenue in the Canadian market during the fourth quarter of 2019 and by strategic price reductions across various adult use products in Canada in the fourth quarter of 2020.
Jerry Barbato
executiveFor the Rest of World segment, gross loss in Q4 2020 came to $16.7 million — that's a $4.8 million reduction in losses versus the fourth quarter of 2019. The year-over-year improvement came mainly from lower inventory write-downs, partly offset by higher cost of sales — largely due to third-party flower purchases — along with a decline in wholesale sales out of the Canadian market. As we work toward building an efficient global supply chain for our Rest of World segment through 2021 and beyond, we expect gross margins to keep fluctuating as price and mix shift quarter to quarter. Adjusted EBITDA loss for the Rest of World segment in Q4 2020 was $36.4 million, which represents an $11 million decrease in losses compared with the fourth quarter of 2019. That improvement was mainly driven by a lower gross loss, reduced sales and marketing costs, and a decline in general and administrative expenses. Moving to the U.S. segment, net revenue for the fourth quarter of 2020 was $3.5 million, up 30% from the prior year period. Year-over-year revenue growth was primarily driven by expansion of existing product lines, the launch of new hemp derived CBD products, and strength in our direct-to-consumer business fueled by holiday promotions.
Jerry Barbato
executiveFor the U.S. segment in Q4 2020, gross profit came in at $1.8 million, which is up $400,000 compared with the fourth quarter of 2019. The adjusted EBITDA loss for that U.S. segment in Q4 2020 totaled $11.8 million, and that means losses grew by $10.6 million versus the fourth quarter of 2019. What drove that loss increase was mainly higher sales and marketing spending tied to brand development, along with higher general and administrative expenses. On an overall basis, Cronos Group posted lower net income than in the prior-year period, and the main reason was the change in fair value of the financial derivative liability linked to Altria's investment, which gets more detailed treatment in the 10-K. During Q4 2020, the company booked a non-cash loss of $53.5 million tied to the change in fair value of those financial derivative liabilities. Cronos still anticipates that significant earnings volatility may be reported, driven chiefly by the quarterly fair value adjustments connected to movements in Cronos Group's stock price. Moving to the balance sheet, the company closed the quarter with roughly $1.3 billion in cash and short-term investments, a figure that stayed relatively flat compared with the third quarter of 2020.
Jerry Barbato
executiveFor the quarter, capital expenditures came in at $11 million. That figure covers investments tied to Cronos Fermentation, the Peace Naturals campus, our facility in Israel, and the new ERP system we've put in place. Our commitment to deploying capital in a disciplined way remains firm, and we'll only do so in ways that match our strategic priorities. The work our teams are carrying out around the world continues to encourage me. With that, I'll hand things over to Kurt for closing remarks ahead of Q&A.
Kurt Schmidt
executiveThanks, Jerry. It's evident that consumers are choosing our products, and our brands keep connecting in the markets where we operate. Despite the pandemic's unprecedented impacts, the past year brought chances to grow. And we're genuinely driven to carry that growth forward in 2020. By focusing on continuing to develop successful teams, refining regional strategies, backing our breakthrough technologies and R&D progress, and establishing leading brands, I'm confident we can keep winning as an organization and guide the global cannabinoids industry into its next growth phase. With our strong balance sheet, a best-in-class strategic partner, and a team built to win, I'm excited about the chance to lead Cronos in the next chapter. With that, let's open things up now for the question line.
Operator
operatorOur first question today is from Andrew Carter at Stifel.
Andrew Carter
analystLet me begin by asking about gross margin. On that topic, I realize further swings are expected, though absent that charge, the margin would have improved. So first, roughly how would you characterize your inventory levels? Beyond that, during the year you'll have internal supply for GroCo becoming available, along with Israel domestic coming online. Given that, ought we to expect considerable gross margin expansion in Rest of World, at least on an underlying basis, across 2021?
Kurt Schmidt
executiveMy sense is that you'll continue to witness certain swings in gross margin, given that pricing and mix shift each quarter, and that's really what I want to address. Those mix shifts aren't just tied to the items we carry in Canada — they also reflect the Israeli market change you mentioned, particularly when you consider the ROW segment, where we're only in the early stages in Israel since it's still ramping up. So once that grows into a larger share, you'll see additional mix shifts as we introduce oil in that category. And as you're aware, we made some price cuts during the second half of 2020. Margins differ by product and by province across Canada, which contributes to some of that mix movement as well. And although we purchase third-party flower each quarter, pricing keeps declining. You have to work through the inventory acquired in earlier quarters. So on the flower side of the business, we anticipate that cost per gram will have an effect on that, though it depends on how mix shifts. So predicting what it will be down the road is difficult, in my view. Still, we clearly anticipate some margin volatility ahead.
Operator
operatorThe next question is from Vivien Azer at Cowen.
Vivien Azer
analystI'd like to pick up on that thread of questions, if that's alright. I just want to get a clearer picture of the output you're generating right now, along with your inventory, since it seems to me we're picking up somewhat conflicting signals regarding price deflation. I believe net for the whole category, on a weighted average basis, yes, it is deflationary, given that you and numerous other competitors have rolled out value and deep value offerings. But I'm not picking up nearly as much price compression in the premium segments. So I'm simply trying to figure out what you're producing today — is that also exposed to price deflation risk, and then what incremental risk remains on your balance sheet?
Jerry Barbato
executiveOkay, Vivien. My view remains that across every price tier in Canada — premium, mid-tier, and value — we're in a deflationary environment, and that shows up in each category. So when we examined what we offer under COVE and Spinach and worked to keep our pricing competitive, you can see we made some of those price adjustments during the second half of the year. And when that stops, I can't say. On inventory, I'd say we're sitting in a sensible spot. We're just a bit above where we stood at the close of 2019. And as Kurt mentioned in his prepared remarks, that revenue channel has grown by almost 100%. So I'm at ease that the inventory we hold fits the scale of our business.
Operator
operatorRahul Sarugaser from Raymond James has the next question.
Rahul Sarugaser
analystOne thing that stood out as a real bright spot was the fact that revenue in the U.S. CBD channel doubled. Kurt, you mentioned some of the challenges around U.S. retail, and obviously none of us has a crystal ball about what happened after COVID, so could you talk a bit about how you see that trajectory playing out? Do you expect it to keep doubling quarter-over-quarter, and is there any more color you can give on expansion in that channel?
Kurt Schmidt
executiveYeah, well, I think the effect of COVID — with limited store openings and other pandemic-related factors — has definitely done damage. But as vaccinations continue rolling out, we believe things will begin to turn, right, and we're already seeing early positive signs there; ultimately it comes down to the strength of the brand and investment. And for — in the U.S. we're happy to — we're very pleased, we just announced the ULTA partnership, which is certainly going to be an accelerant for that business. And you're going to see marketing investment behind both our Lord Jones and ULTA brands. So, again, our focus was on growth. And as we get through this pandemic, when it comes to the U.S., I think the fact — the second half of the year, everybody feels fairly confident that we will be fairly well — with the vaccine, fairly well penetrated. So, we should see the retail sector continuing to open up, and that's a good sign, obviously a good sign for us.
Rahul Sarugaser
analystThen a quick follow-up, if I could. As you know, one thing we're pretty focused on is the Ginkgo partnership and the various initiatives — you mentioned the emphasis on CBG. Mike earlier said September was the target timeline for the first Fermentation products to hit shelves. Are we still on that timeline? And how should we think about product formats, and possibly expanding Fermentation-based cannabinoids across your products?
Kurt Schmidt
executiveYes, at present our expectation is that commercialization will be reached in Q3 of 2021. And, as I mentioned during my opening remarks, our priority really is the rare cannabinoids, since we think that will give us a stronger capacity to innovate and to give consumers products that are differentiated. So that has us genuinely excited. I don't want to get into the specific products at this moment. But we are making solid progress. So, once more, we remain on track, and we feel quite good about that. And clearly, rare cannabinoids provide some truly unique, differentiated consumer products and benefits that we obviously intend to focus on.
Operator
operatorJohn Zamparo from CIBC has the next question.
John Zamparo
analystI’d like to ask about how the internal team focused on U.S. markets is being formed. More specifically, there are actions available right now that would let you put capital to work in the U.S. absent full-scale legalization—whether that means optionality deals, arrangements involving CBG brands, or possibly partnerships with retailers. Any thoughts or observations you have on that would be helpful.
Kurt Schmidt
executiveYes, Kurt here, and I'll get us started. Still, I believe Mike's perspective is worth hearing on this, so he'll weigh in too. As all of you are aware, regarding active or truly direct investments within the U.S., it matters that we secure federal action removing cannabis—or THC—as a controlled substance. Alongside that sits the operational dimension, and there are numerous targeted areas that permit genuine streamlining and an effectively functioning industry. And once more, Mike is evaluating a variety of entry strategies beyond those active investments. So it's excellent that Mike offers his thoughts on this right now.
Mike Gorenstein
executiveSure, thank you, Kurt. Hi, John. So in the U.S., we really tend to think about three phases. The first one is the phase we're in right now, where, as Kurt mentioned, the legal regime prevents us from entering directly and actively. But I think there are still certain levers we can pull. The next phase is really the one you hear discussed, regarding the government at present, where cannabis prohibition in the U.S. comes to an end, and that would let us participate actively and directly in states that have established responsible cannabis frameworks. And then finally, there's a responsible and comprehensive framework at the federal level that allows for interstate commerce and high product standards. And when we consider that third phase, that's really where our strategy is centered on positioning ourselves, right now, so that we can ultimately deliver value there. And we still believe it will be authentic brands, built on technology, that make the products different. And that is what will ultimately drive terminal value. So any levers or anything we're looking to pull now is really about thinking ahead, about how we are best set up to win.
Mike Gorenstein
executiveAnd that is genuinely the area we're concentrating on.
John Zamparo
analystIf I could just come back to that topic—specifically how the USCC came together. My initial assumption was that perhaps the objectives of those—of the parties taking part might not have lined up perfectly. So what should we read into the fact that participants from both America and Canada are joining forces on this effort? And would one of the USCC's near-term priorities be a tactical push to accomplish something concrete, such as the SAFE Banking Act? Or does it lean more toward—perhaps a more transformative, longer-term objective?
Kurt Schmidt
executiveYes, this is Kurt. That's a good question. From our perspective, what's really required is a comprehensive approach, and that covers a number of areas—for instance, tackling historic injustice affecting communities of color, which have been hit disproportionately hard in this space. It could involve executive orders that, in our view, ought to be coordinated among the various departments, which will be very important—departments like the DOJ, Treasury, FDA and HHS—and legislative action would add further clarity, and there are multiple paths you could pursue. And via the council, and via our partnership with Altria, we're heavily focused on having a seat at the table and being able to deliver on that. But fundamentally, we truly do need a comprehensive approach so that we can actually create the right environment for the market and for the various issues unfolding right now in the U.S. And we're fairly confident that things are beginning to head in the right direction.
Operator
operatorMichael Lavery at Piper Sandler has the next question.
Michael Lavery
analystI'd just like to ask if you could say a bit more about CBG. It sounds as though you have the biosynthesis markdown. But when it comes to the consumer, how much educating do you need to do regarding its benefits? And what's your go-to-market plan for it?
Kurt Schmidt
executiveThat's a great question. Our consumer insights group is extremely capable. So alongside the work of developing these rare cannabinoids, we're examining the product innovation angle — how we'll communicate it, and which products we'll incorporate it into. I'd rather not detail exactly what we plan to do. But all of that is progressing well. Another interesting point about these rare cannabinoids: if you Google THCV, CBN, and CBG, you'll find a wealth of knowledge and awareness regarding how people discuss them and the benefits of these products. So in certain respects, consumers are quite focused on them, they understand them, and they grasp some of the benefits. And so that's somewhat built in at present. But again, rare cannabinoids are very difficult to call because achieving scale with them is very hard. And that's what we believe we can deliver. And we could leverage our innovation and consumer insights and our innovation teams to develop some genuinely unique products that deliver on those consumer promises.
Michael Lavery
analystTurning to GroCo and the capacity we're adding—which is fairly unusual in this industry right now—could you give us a picture of the competitive landscape and how you view capacity more generally? Has it been right-sized, or does excess capacity still exist? And is this initiative mainly about guaranteeing quality products, or what's your thinking behind bringing that online?
Kurt Schmidt
executiveI'd describe it as a hybrid setup, really — that way we're able to source from GroCo as well as from other third-party biomass suppliers. So having that flexibility matters to us. GroCo got its cultivation license back in 2012. We therefore anticipate that facility becoming operational in stages, starting in the first half of '21. The advantage for us is partnering with an expert — they know this field inside out — and they're able to supply high-quality biomass at a low cost. But really, at this point it comes down to running that hybrid model within the Canadian market. And that's more or less the same approach we've also taken with Israel.
Operator
operatorMatt Bottomley from Canaccord has the next question.
Matt Bottomley
analystI'm just wondering whether you could give us a bit more detail on what you're seeing in the adult use market when it comes to your brand penetration — for instance, the sequential shifts, I suppose, in the number of orders the provinces are placing with you? And then, do you have any additional data on how your products are selling through to end consumers this quarter compared with last quarter, out of the retail touchpoints, if that's right?
Kurt Schmidt
executiveRegarding revenue guidance, we aren’t providing any — yes, Jerry, would you like to take that one?
Jerry Barbato
executiveRight, we don’t provide forward-looking revenue guidance. Still, I think a few of the COVID effects you’ve observed—particularly in Ontario, where stores shut and shifted to curbside pickup—were visible early in the pandemic when it first hit, and growth eased slightly then. So you saw that across categories in December and January. We believe our brand penetration has held up quite well; you saw sequential growth each quarter in 2020, and I think we’re making strong progress on that front.
Matt Bottomley
analystDo you have any kind of estimate — I realize you don't give one for presenting up — but any rough goalposts for where you see your branded market share in Canada at this point, and how it has shifted over roughly the past year?
Jerry Barbato
executiveRight, there isn't much solid data up in Canada to really pin that down. In typical CPG you'd have Nielsen numbers or another kind of quantitative measure. I mean, we do our own internal tracking. But it's tough, and it's also hard to assess — with all these big value players and larger formats entering the market, looking at it that way is a bit of a challenge for us. So our real focus is on growing those brands and on revenue growth.
Operator
operatorThe last question we'll take is from Thea Wang at Jefferies.
Thea Wang
analystI'm posing this question for my analyst, Owen Bennett. I'd like to briefly address the product mix, since right now cannabis flowers still account for most of the sales. And sequentially, the extracts have shown only a very limited increase. So I'm wondering what your outlook is on the product mix, and do you expect it to remain at roughly the current proportion levels going forward?
Kurt Schmidt
executiveKurt here. So, one thing we're noticing is the pattern we've had throughout COVID, and Jerry touched on that a moment ago. With consumers under lockdown and moving around less in general, we've clearly observed a shift in preferences toward purchasing larger quantities within the flower category rather than base or even pre-rolls, since that option makes more sense, and because regrettably over the past three months hardly anyone has been going anywhere. That has pushed our sales, along with the Canadian markets, to lean more heavily toward the flower category. That said, as conditions improve and retail begins reopening while people regain mobility, we don't anticipate this lasting over the long term. So once more, we're eager to bring out new and innovative products throughout the 2.0 spectrum during the course of 2021. So yes, we do have plans. And again, we're quite hopeful that as vaccination rolls out and things return to normal, we'll see the market evolve the way it did before COVID.
Operator
operatorThank you, everyone, for joining this conference today. That brings us to the end of the call. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.